32 results about "AORTIC VALVULAR STENOSIS" patented technology

A valve prosthesis which is especially useful in the case of aortic stenosis and capable of resisting the powerful recoil force and to stand the forceful balloon inflation performed to deploy the valve and to embed it in the aortic annulus, comprises a collapsible valvular structure and an expandable frame on which said valvular structure is mounted. The valvular structure is composed of physiologically compatible valvular tissue that is sufficiently supple and resistant to allow the valvular structure to be deformed from a closed state to an opened state. The valvular tissue forms a continuous surface and is provided with strut members that create stiffened zones which induce the valvular structure to follow a patterned movement in its expansion to its opened state and in its turning back to its closed state.

Prosthetic devices as described for use in the treatment of aortic stenosis in the aortic valve of a patient's heart, the prosthetic device having a compressed state for transarterial delivery and being expandable to an expanded state for implantation. The prosthetic device includes an expandable metal base (10) constructed so as to be implantable in the expanded state of the prosthetic device in the aortic annulus of the aortic valve; and an inner envelope lining (11) tune inner surface of the metal base (10). The inner envelope, in the expanded state of the prosthetic device, extends into the aorta and is of a diverging conical configuration, in which its diameter gradually increases from its proximal end within the aortic annulus to its distal end extending into the aorta, such as to produce, during systole, a non-turbulent blood flow into the aorta with pressure recovery at the distal end of the inner envelope. Preferably, the distal end includes a prosthetic valve which is also concurrently implanted, but such a prosthetic valve may be implanted separately in the aorta Also described are preferred methods of implanting such prosthetic devices.

Disclosed is a method for removing deposits from an in vivo tissue, such as removing calcified plaque from a calcified aortic valve by removing the deposits with the help of shock waves produced by a light-source such as a laser in an aqueous liquid in proximity of the tissue as well as a shock-wave generating device useful in implementing the method. Disclosed is a minimally invasive valve-sparing treatment of calcific aortic stenosis.

In various embodiments, provided herein are devices, systems and methods using two, three or more pigtails for precisely imaging an aortic valve complex with minimal contrast and/or for advancing an instrument, such as a wire, or device, such as a transcatheter valve, across an aortic valve. In various embodiments, these devices, systems and methods may be used to diagnose and/or treat patients with aortic stenosis, other valvular heart disease or other cardiovascular or non cardiovascular disease, facilitating precise contrast or drug or device delivery, precise pressure measurement and/or precise drainage or sampling. In some embodiments, each of the multiple pigtails of the device may be advanced independently of one another in multiple directions and at multiple lengths of deployment to optimize position.

Provided is an expansible catheter balloon that has a spreadable outer diameter controllable easily in treatments for a calcific aortic stenosis, rheumatic and congenital aortic stenoses and others, and that can be effectively prevented from being freely shifted and can easily be fixed at a predetermined position. The catheter balloon includes a balloon having shoulder parts made of a non-expansible material or made low-expansible and an expandable waist part, and a catheter having a catheter body to which this balloon is fitted.

The invention provides an angiocarpy sacculus dilating catheter, belonging to the angiocarpy sacculus dilating catheter. The dilating catheter comprises a lumen connector, a Y-shaped connector, a protective sleeve, an injection port, a canal, a mark ring and a sacculus, wherein one end of the Y-shaped connector is connected with the lumen connector, another end of the Y-shaped connector is provided with the injection port, and the third end of the Y-shaped connector is connected with the canal and is provided with the protective sleeve; and the front end of the canal is provided with the sacculus. The angiocarpy sacculus dilating catheter has the advantages that the sacculus dilating catheter is made of Nylon 12 and PEBAX with good biocompatibility and high pressure resistance, has good adaptability, large bursting pressure, unique structure and high safety, can be applied to interventional therapy on congenital stenosis of pulmonary valve, aortic stenosis and other diseases, and adopts single lumen sleeved sacculus structure to lead smoothness of injection and pumpback; the connection of the sacculus and the canal adopts welding process, the sacculus and the canal are integrated to greatly reduce the risk of pressuring breaking; and the thread lumen and the injection lumen are respectively arranged to reduce the risk of liquid leakage.

The invention provides a decompression assist device for cardiac aortic stenosis or incompetence. The decompression assist device is characterized by comprising a first clamp piece and a second clamp piece connected through a connecting shaft; the first clamp piece and the second clamp piece comprise a clamp arm and a clamp holder respectively; each of the clamp arms is provided with a bent arm; the front end of each of the bent arms is provided with an artery arm; a spring is arranged on the middle section of each of the bent arms; two ends of each of the springs are connected with the middle section of each of the bent arms of the first clamp piece and the second clamp piece; and each of the clamp holders is connected with an atrium support and positioning holes are formed on the edge of each of the atrium support.

Provided is an expansive catheter balloon that has a spreadable outer diameter controllable easily in treatments for a calcific aortic stenosis, rheumatic and congenital aortic stenosis and others, and that can be effectively prevented from being freely shifted and can easily be fixed at a predetermined position. The catheter balloon includes a cylindrical balloon part that is made non-expansive or low-expansive, and a band part made of a stretchable elastic body. When a stretching force is not applied, the band part has a shorter diameter than a spread diameter of the balloon part and is wound around the center of the balloon part.

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

A system (CV stenosis system) and method for noninvasive cardiac stenosis monitoring, diagnosis, analysis and reporting are disclosed. The CV stenosis system includes an in-ear biosensor system and a data analysis system. The in-ear biosensor system includes at least one earbud placed at or within an ear canal of an individual, where the at least one earbud includes one or more acoustic/vibration sensors that operate in both infrasonic and audible frequency ranges and detect biosignals from the individual. The data analysis system receives the biosignals from the biosensor system, separates the biosignals into components including infrasonic cardiac signals, and determines a type and level/severity of cardiovascular stenosis of the individual based upon the biosignals. In embodiments, the CV stenosis system can detect aortic stenosis and determine its severity, and detect stenoses of the left and right carotid arteries.

The system (102) includes a digital information repository (104) configured to store an aortic valve area measurement, an average tranaortic pressure gradient measurement, and a peak aortic jet velocity measurement of a subject of interest. The system also includes a computing device (106). The computing device includes a memory (110) configured to store instructions (120) for an aortic stenosis classifier (122). The computing device further includes a processor (108) configured to execute stored instructions for the aortic stenosis classifier, the subject's severity of aortic stenosis is classified based at least on the subject's aortic valve area measurements, the average tranaortic pressure gradient measurements, and the peak aortic jet velocity measurements. The computing device also includes a display configured to display the severity.

The present disclosure relates to compositions of N-acetylcysteine for use in treating aortic stenosis. Methods of treating aortic stenosis in a subject comprising administering to said subject an effective amount of N-acetylecysteine (NAC) or other thiol-reactive compound, or agents that inhibit TGF-Beta activation and/or signaling.